Showing results (81-90 of 111) with videos related to
Sort By:
Pageof 12
Clinical Drug Investigation|November 17, 2016
Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study RegionsKayo Fujita, Masayuki Kaneko, Mamoru NarukawaJournal of Cancer Research and Clinical Oncology|February 25, 2014
Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancerMasayuki Aboshi, Masayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|September 18, 2018
Comparison of Approved Dosages for Pediatric and Adult Populations Based on US Labeling InformationKeizo Hanada, Masayuki Kaneko, Mamoru NarukawaEuropean Journal of Clinical Pharmacology|May 27, 2019
Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancerKenji Yamashita, Masayuki Kaneko, Mamoru NarukawaJournal of Oncology Practice|November 15, 2017
Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology ProductsAtsushi Hyogo, Masayuki Kaneko, Mamoru NarukawaClinical Drug Investigation|December 2, 2023
Comparison of the Incidence of Adverse Events Between Japanese and Non-Japanese Healthy Subjects in Phase I Studies: A Systematic Review and Meta-AnalysisSatomi Sakurai, Kazuhiro Matsui, Mamoru NarukawaInternational Journal of Clinical Oncology|October 15, 2020
Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall populationToshiyuki Tamai, Masayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|September 22, 2020
Analysis of Pediatric Drug Approval Lag in JapanEiji Ueyama, Masayuki Kaneko, Mamoru NarukawaClinical Pharmacology in Drug Development|April 29, 2016
Impact of Clinical Response on Different Approved Doses in Japan and the United StatesYuko Sugita, Eisuke Inoue, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|May 2, 2018
Investigation of the Study Characteristics Affecting Clinical Trial Quality Using the Protocol Deviations Leading to Exclusion of Subjects From the Per Protocol Set Data in Studies for New Drug Application: A Retrospective AnalysisNorihito Kohara, Masayuki Kaneko, Mamoru NarukawaPageof 12